Molecular Partners AG (MOLN) — Capital Reinvestment Ratio

Latest as of March 2022: 0.00x

Molecular Partners AG (MOLN) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow (CHF163.56 Million) in capital expenditures (CHF380.00K). See MOLN net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

CHF163.56 Million
CHF

Capital Expenditures

CHF380.00K
CHF

Data as of

Mar 2022
Most recent filing

Molecular Partners AG Capital Reinvestment Ratio (2015–2022)

This chart tracks Molecular Partners AG's Capital Reinvestment Ratio across 2 annual periods. Check cash flow reinvestment rate of Molecular Partners AG to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Molecular Partners AG (2015–2022)

Year-by-year Capital Reinvestment Ratio for Molecular Partners AG from 2015 to 2022. For live market cap and broader valuation context, see market cap of Molecular Partners AG.

Year Reinvestment Ratio Operating CF (CHF) Capital Expenditures YoY Change
2022 0.01x CHF118.57 Million CHF1.42 Million ▼ -77.2%
2015 0.05x CHF26.50 Million CHF1.39 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow